Market Overview

FLX Bio to Present at 37th Annual J.P. Morgan Healthcare Conference


FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on
the development of oral small-molecule drugs that target immune drivers
of cancer and other immune-related disorders, today announced that Brian
Wong, M.D., Ph.D., CEO will present at the 37th Annual J.P.
Morgan Healthcare Conference on Wednesday, January 9, 2019 at 7:30 a.m.
Pacific Standard Time in San Francisco, CA. Dr. Wong will provide a
corporate update and company overview.

About FLX Bio

FLX Bio, Inc. is a privately-held biopharmaceutical company focused on
the discovery, development and commercialization of best-in-class, oral
small molecule therapeutics for the treatment of cancers and other
immune disorders. Our lead compounds inhibit the CCR4 pathway which
plays a key role in both suppressing the immune response to cancer and
in the initiation, progression and persistence of allergic inflammation.
We leverage big data and machine learning together with our advanced
drug discovery capabilities and deep biology expertise, to develop
therapeutics that address key pressure points in pathways that propagate
an abnormal immune response.

Located in South San Francisco, Calif., and funded by leading investors,
including The Column Group (TCG), Kleiner Perkins (KP), Topspin
Partners, GV (formerly Google Ventures) and Celgene Corporation, FLX Bio
has assembled a leadership team and advisory group with a proven track
record of success and team of scientists with substantial knowledge and
expertise in drug discovery and translational areas essential to execute
on this approach. For more information, please visit

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at